Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Monoclonal antibodies against interleukin-5, a potent eosinophilic cytokine and growth factor, have not shown efficacy in three clinical trials 1 – 3 in patients with asthma, despite the effectiveness of this treatment in reducing the number of eosinophils in the airway and blood. This finding has r...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2009-03, Vol.360 (10), p.985-993 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 993 |
|---|---|
| container_issue | 10 |
| container_start_page | 985 |
| container_title | The New England journal of medicine |
| container_volume | 360 |
| creator | Nair, Parameswaran Pizzichini, Emilio Pizzichini, Marcia M.M Kjarsgaard, Melanie Inman, Mark D Efthimiadis, Ann Hargreave, Frederick E O'Byrne, Paul M |
| description | Monoclonal antibodies against interleukin-5, a potent eosinophilic cytokine and growth factor, have not shown efficacy in three clinical trials
1
–
3
in patients with asthma, despite the effectiveness of this treatment in reducing the number of eosinophils in the airway and blood. This finding has raised questions about the role of eosinophils in the pathophysiology of asthma.
We reasoned that eosinophils may be in the pathobiologic chain of causation in a rare subgroup of patients with asthma who have persistent sputum eosinophilia despite treatment with oral prednisone. To test this hypothesis, we examined the prednisone-sparing effect of mepolizumab by assessing clinical . . . |
| doi_str_mv | 10.1056/NEJMoa0805435 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67006780</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1656591541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-8fe7b2d077185d0d13b51482eaa6cea595c6242309bba94a98d4a327f25ec27b3</originalsourceid><addsrcrecordid>eNp10M9L3EAUB_ChVOpqe-xVQkFvqW9-J0fR1baoFWzPYZK8sLNkZuJMguhfbxaXLhV8l3f58H2PLyFfKXynINXp7fLXTTBQgBRcfiALKjnPhQD1kSwAWJELXfJ9cpDSGuahovxE9mnJlFCFXpCLGxxCb58nZ-qsCzG7i9h6m4LH_AIH9C36MTtL48qZ7NGOq-x-mMbJZcuQrA_DyvbWfCZ7nekTftnuQ_L3cvnn_Ed-_fvq5_nZdd5IUGNedKhr1oLWtJAttJTXkoqCoTGqQSNL2SgmGIeyrk0pTFm0wnCmOyaxYbrmh-TkNXeI4WHCNFbOpgb73ngMU6qUBlC6gBl-ewPXYYp-_q1ijJeUab1B-StqYkgpYlcN0ToTnyoK1abb6r9uZ3-0DZ1qh-1Ob8ucwfEWmNSYvovGNzb9c4wy0CBh55xLlce1e-fgCy2Ci9Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223912770</pqid></control><display><type>article</type><title>Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Nair, Parameswaran ; Pizzichini, Emilio ; Pizzichini, Marcia M.M ; Kjarsgaard, Melanie ; Inman, Mark D ; Efthimiadis, Ann ; Hargreave, Frederick E ; O'Byrne, Paul M</creator><creatorcontrib>Nair, Parameswaran ; Pizzichini, Emilio ; Pizzichini, Marcia M.M ; Kjarsgaard, Melanie ; Inman, Mark D ; Efthimiadis, Ann ; Hargreave, Frederick E ; O'Byrne, Paul M</creatorcontrib><description>Monoclonal antibodies against interleukin-5, a potent eosinophilic cytokine and growth factor, have not shown efficacy in three clinical trials
1
–
3
in patients with asthma, despite the effectiveness of this treatment in reducing the number of eosinophils in the airway and blood. This finding has raised questions about the role of eosinophils in the pathophysiology of asthma.
We reasoned that eosinophils may be in the pathobiologic chain of causation in a rare subgroup of patients with asthma who have persistent sputum eosinophilia despite treatment with oral prednisone. To test this hypothesis, we examined the prednisone-sparing effect of mepolizumab by assessing clinical . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa0805435</identifier><identifier>PMID: 19264687</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Administration, Inhalation ; Administration, Oral ; Adrenergic beta-Agonists - therapeutic use ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Asthma ; Asthma - drug therapy ; Asthma - physiopathology ; Biological and medical sciences ; Chronic obstructive pulmonary disease, asthma ; Cytokines ; Double-Blind Method ; Drug dosages ; Drug Therapy, Combination ; Eosinophilia - drug therapy ; Eosinophils ; Female ; Forced Expiratory Volume - drug effects ; General aspects ; Glucocorticoids - administration & dosage ; Glucocorticoids - therapeutic use ; Humans ; Interleukin-5 - antagonists & inhibitors ; Interleukin-5 - immunology ; Leukocyte Count ; Male ; Medical sciences ; Middle Aged ; Pneumology ; Prednisone - administration & dosage ; Prednisone - therapeutic use ; Secondary Prevention ; Sputum - immunology</subject><ispartof>The New England journal of medicine, 2009-03, Vol.360 (10), p.985-993</ispartof><rights>Copyright © 2009 Massachusetts Medical Society. All rights reserved.</rights><rights>2009 INIST-CNRS</rights><rights>2009 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-8fe7b2d077185d0d13b51482eaa6cea595c6242309bba94a98d4a327f25ec27b3</citedby><cites>FETCH-LOGICAL-c506t-8fe7b2d077185d0d13b51482eaa6cea595c6242309bba94a98d4a327f25ec27b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa0805435$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223912770?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2757,2758,26102,27923,27924,52381,54063,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21207050$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19264687$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nair, Parameswaran</creatorcontrib><creatorcontrib>Pizzichini, Emilio</creatorcontrib><creatorcontrib>Pizzichini, Marcia M.M</creatorcontrib><creatorcontrib>Kjarsgaard, Melanie</creatorcontrib><creatorcontrib>Inman, Mark D</creatorcontrib><creatorcontrib>Efthimiadis, Ann</creatorcontrib><creatorcontrib>Hargreave, Frederick E</creatorcontrib><creatorcontrib>O'Byrne, Paul M</creatorcontrib><title>Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Monoclonal antibodies against interleukin-5, a potent eosinophilic cytokine and growth factor, have not shown efficacy in three clinical trials
1
–
3
in patients with asthma, despite the effectiveness of this treatment in reducing the number of eosinophils in the airway and blood. This finding has raised questions about the role of eosinophils in the pathophysiology of asthma.
We reasoned that eosinophils may be in the pathobiologic chain of causation in a rare subgroup of patients with asthma who have persistent sputum eosinophilia despite treatment with oral prednisone. To test this hypothesis, we examined the prednisone-sparing effect of mepolizumab by assessing clinical . . .</description><subject>Administration, Inhalation</subject><subject>Administration, Oral</subject><subject>Adrenergic beta-Agonists - therapeutic use</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Cytokines</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Drug Therapy, Combination</subject><subject>Eosinophilia - drug therapy</subject><subject>Eosinophils</subject><subject>Female</subject><subject>Forced Expiratory Volume - drug effects</subject><subject>General aspects</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Interleukin-5 - antagonists & inhibitors</subject><subject>Interleukin-5 - immunology</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - therapeutic use</subject><subject>Secondary Prevention</subject><subject>Sputum - immunology</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10M9L3EAUB_ChVOpqe-xVQkFvqW9-J0fR1baoFWzPYZK8sLNkZuJMguhfbxaXLhV8l3f58H2PLyFfKXynINXp7fLXTTBQgBRcfiALKjnPhQD1kSwAWJELXfJ9cpDSGuahovxE9mnJlFCFXpCLGxxCb58nZ-qsCzG7i9h6m4LH_AIH9C36MTtL48qZ7NGOq-x-mMbJZcuQrA_DyvbWfCZ7nekTftnuQ_L3cvnn_Ed-_fvq5_nZdd5IUGNedKhr1oLWtJAttJTXkoqCoTGqQSNL2SgmGIeyrk0pTFm0wnCmOyaxYbrmh-TkNXeI4WHCNFbOpgb73ngMU6qUBlC6gBl-ewPXYYp-_q1ijJeUab1B-StqYkgpYlcN0ToTnyoK1abb6r9uZ3-0DZ1qh-1Ob8ucwfEWmNSYvovGNzb9c4wy0CBh55xLlce1e-fgCy2Ci9Y</recordid><startdate>20090305</startdate><enddate>20090305</enddate><creator>Nair, Parameswaran</creator><creator>Pizzichini, Emilio</creator><creator>Pizzichini, Marcia M.M</creator><creator>Kjarsgaard, Melanie</creator><creator>Inman, Mark D</creator><creator>Efthimiadis, Ann</creator><creator>Hargreave, Frederick E</creator><creator>O'Byrne, Paul M</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20090305</creationdate><title>Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia</title><author>Nair, Parameswaran ; Pizzichini, Emilio ; Pizzichini, Marcia M.M ; Kjarsgaard, Melanie ; Inman, Mark D ; Efthimiadis, Ann ; Hargreave, Frederick E ; O'Byrne, Paul M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-8fe7b2d077185d0d13b51482eaa6cea595c6242309bba94a98d4a327f25ec27b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Inhalation</topic><topic>Administration, Oral</topic><topic>Adrenergic beta-Agonists - therapeutic use</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Cytokines</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Drug Therapy, Combination</topic><topic>Eosinophilia - drug therapy</topic><topic>Eosinophils</topic><topic>Female</topic><topic>Forced Expiratory Volume - drug effects</topic><topic>General aspects</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Interleukin-5 - antagonists & inhibitors</topic><topic>Interleukin-5 - immunology</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - therapeutic use</topic><topic>Secondary Prevention</topic><topic>Sputum - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nair, Parameswaran</creatorcontrib><creatorcontrib>Pizzichini, Emilio</creatorcontrib><creatorcontrib>Pizzichini, Marcia M.M</creatorcontrib><creatorcontrib>Kjarsgaard, Melanie</creatorcontrib><creatorcontrib>Inman, Mark D</creatorcontrib><creatorcontrib>Efthimiadis, Ann</creatorcontrib><creatorcontrib>Hargreave, Frederick E</creatorcontrib><creatorcontrib>O'Byrne, Paul M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nair, Parameswaran</au><au>Pizzichini, Emilio</au><au>Pizzichini, Marcia M.M</au><au>Kjarsgaard, Melanie</au><au>Inman, Mark D</au><au>Efthimiadis, Ann</au><au>Hargreave, Frederick E</au><au>O'Byrne, Paul M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2009-03-05</date><risdate>2009</risdate><volume>360</volume><issue>10</issue><spage>985</spage><epage>993</epage><pages>985-993</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Monoclonal antibodies against interleukin-5, a potent eosinophilic cytokine and growth factor, have not shown efficacy in three clinical trials
1
–
3
in patients with asthma, despite the effectiveness of this treatment in reducing the number of eosinophils in the airway and blood. This finding has raised questions about the role of eosinophils in the pathophysiology of asthma.
We reasoned that eosinophils may be in the pathobiologic chain of causation in a rare subgroup of patients with asthma who have persistent sputum eosinophilia despite treatment with oral prednisone. To test this hypothesis, we examined the prednisone-sparing effect of mepolizumab by assessing clinical . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>19264687</pmid><doi>10.1056/NEJMoa0805435</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2009-03, Vol.360 (10), p.985-993 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67006780 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Administration, Inhalation Administration, Oral Adrenergic beta-Agonists - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Asthma Asthma - drug therapy Asthma - physiopathology Biological and medical sciences Chronic obstructive pulmonary disease, asthma Cytokines Double-Blind Method Drug dosages Drug Therapy, Combination Eosinophilia - drug therapy Eosinophils Female Forced Expiratory Volume - drug effects General aspects Glucocorticoids - administration & dosage Glucocorticoids - therapeutic use Humans Interleukin-5 - antagonists & inhibitors Interleukin-5 - immunology Leukocyte Count Male Medical sciences Middle Aged Pneumology Prednisone - administration & dosage Prednisone - therapeutic use Secondary Prevention Sputum - immunology |
| title | Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T08%3A35%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mepolizumab%20for%20Prednisone-Dependent%20Asthma%20with%20Sputum%20Eosinophilia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Nair,%20Parameswaran&rft.date=2009-03-05&rft.volume=360&rft.issue=10&rft.spage=985&rft.epage=993&rft.pages=985-993&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa0805435&rft_dat=%3Cproquest_cross%3E1656591541%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223912770&rft_id=info:pmid/19264687&rfr_iscdi=true |